BioCentury | Aug 17, 2015
Strategy

Shifting MS spending

Payers are finally getting - and using - the tools to end uninterrupted price increases for multiple sclerosis drugs as a result of an abundance of options, greater willingness to steer prescribing choices, and the entrance of...
BC Extra | Aug 7, 2015
Top Story

CVS releases 2016 formulary

Pharmacy benefit manager CVS Health Corp. (NYSE:CVS) released its 2016 formulary, which includes a list of 119 excluded drugs. Multiple sclerosis (MS) drugs Plegridy peginterferon beta-1a from Biogen Inc. (NASDAQ:BIIB) and Extavia interferon beta-1b from...
BC Week In Review | Nov 12, 2012
Company News

UnitedHealth Group sales and marketing update

UnitedHealth said it will no longer redeem manufacturer-provided coupon cards for six Tier 3 specialty drugs, effective Jan. 1, 2013. The provider said the decision is expected to manage rising medication costs associated with specialty...
BioCentury | Nov 1, 2010
Regulation

Biosimilar Fault Lines

The passage of the Patient Protection and Affordability Act seven months ago created a biosimilars pathway but left FDA a great deal of discretion to create the rules of the road. The battle over those...
BioCentury | Sep 27, 2010
Strategy

Marketing: Gilenya's uptake

Even though Gilenya fingolimod from Novartis AG is The first oral drug approved to treat relapsing forms of multiple sclerosis, the sphingosine 1-phosphate receptor agonist isn't likely to immediately supplant injectables in the front-line setting,...
BioCentury | Jun 14, 2010
Regulation

Fingolimod: Test, then use

An FDA advisory committee has given the agency a strong recommendation to approve fingolimod from Novartis AG as the first oral treatment for MS - indeed, backing first-line use of the drug - even though the panel...
BC Week In Review | Jun 7, 2010
Company News

Biogen Idec, Bayer, Merck KGaA, Novartis, Pfizer autoimmune news

Bayer filed suit against Biogen Idec in the U.S. District Court for the District of New Jersey alleging that Biogen Idec's U.S. Patent No. 7,588,755 is invalid and not infringed by Bayer's marketing of Betaseron...
BC Innovations | Apr 22, 2010
Cover Story

Markers for interferon responsiveness in MS

Although β-interferons are standard of care for relapsing-remitting multiple sclerosis, with global sales totaling more than $6 billion in 2009, the drugs don't work in about 20% to 25% of patients. Researchers at Stanford University...
BioCentury | Feb 1, 2010
Strategy

57 flavors of experience

The announcement that pharma industry newcomer Joe Jimenez will take over the CEO post at Novartis AG has sparked speculation that cost-cutting will follow. But a look at his track record in consumer goods reveals...
BioCentury | Jan 11, 2010
Finance

Post-Launch Report

Post-Launch Report Sales through 3Q09 of selected drugs approved in 2008 and for which the companies below disclose sales. $M Company Product Indication 2008 approval 2009 sales through 9/30 Adolor (NASDAQ:ADLR)/GlaxoSmithKline (LSE:GSK; NYSE:GSK) Entereg alvimopan...
Items per page:
1 - 10 of 21